JP7292306B2 - 処置に対する応答をモニターする方法 - Google Patents

処置に対する応答をモニターする方法 Download PDF

Info

Publication number
JP7292306B2
JP7292306B2 JP2020555818A JP2020555818A JP7292306B2 JP 7292306 B2 JP7292306 B2 JP 7292306B2 JP 2020555818 A JP2020555818 A JP 2020555818A JP 2020555818 A JP2020555818 A JP 2020555818A JP 7292306 B2 JP7292306 B2 JP 7292306B2
Authority
JP
Japan
Prior art keywords
cancer
wnt
subject
timp
mmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521437A (ja
JP2021521437A5 (cg-RX-API-DMAC10.html
Inventor
ティナ・ラブラノス
クリステン・ジョルジウ
Original Assignee
バイオノミックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018901242A external-priority patent/AU2018901242A0/en
Application filed by バイオノミックス リミテッド filed Critical バイオノミックス リミテッド
Publication of JP2021521437A publication Critical patent/JP2021521437A/ja
Publication of JP2021521437A5 publication Critical patent/JP2021521437A5/ja
Application granted granted Critical
Publication of JP7292306B2 publication Critical patent/JP7292306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020555818A 2018-04-13 2019-04-12 処置に対する応答をモニターする方法 Active JP7292306B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901242 2018-04-13
AU2018901242A AU2018901242A0 (en) 2018-04-13 Method of monitoring response to a treatment
PCT/AU2019/050334 WO2019195897A1 (en) 2018-04-13 2019-04-12 Method of monitoring response to a treatment

Publications (3)

Publication Number Publication Date
JP2021521437A JP2021521437A (ja) 2021-08-26
JP2021521437A5 JP2021521437A5 (cg-RX-API-DMAC10.html) 2022-04-08
JP7292306B2 true JP7292306B2 (ja) 2023-06-16

Family

ID=68163410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555818A Active JP7292306B2 (ja) 2018-04-13 2019-04-12 処置に対する応答をモニターする方法

Country Status (5)

Country Link
US (1) US20210148894A1 (cg-RX-API-DMAC10.html)
JP (1) JP7292306B2 (cg-RX-API-DMAC10.html)
CN (1) CN111971559A (cg-RX-API-DMAC10.html)
AU (1) AU2019251518A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019195897A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944649C (en) * 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541481A (ja) 1999-04-09 2002-12-03 リグズホスピタレット 癌マーカーとしての１型マトリクスメタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−１）
US20140199324A1 (en) 2011-03-24 2014-07-17 Daniel T. Dransfield Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166979A (zh) * 2005-05-11 2008-04-23 霍夫曼-拉罗奇有限公司 化学治疗应答者的确定
US20080305962A1 (en) * 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
TWI504390B (zh) * 2012-09-18 2015-10-21 Univ China Medical 苯醌類化合物應用於抑制黑色素瘤細胞之Ｗｎｔ／β－ｃａｔｅｎｉｎ訊息途徑之用途
RU2702908C2 (ru) * 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541481A (ja) 1999-04-09 2002-12-03 リグズホスピタレット 癌マーカーとしての１型マトリクスメタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−１）
US20140199324A1 (en) 2011-03-24 2014-07-17 Daniel T. Dransfield Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lucidone Promotes the Cutaneous Wound Healing Process via Activation of the Pl3K/AKT, Wnt/beta-Catenin and NF-kappaB SIgnaling Pathways，Biochimica et Biophysica Acta，2017年，Vol.1864，pp.151-168，DOI: 10.1016/j.bbamcr.2016.10.021

Also Published As

Publication number Publication date
EP3775913A1 (en) 2021-02-17
US20210148894A1 (en) 2021-05-20
JP2021521437A (ja) 2021-08-26
AU2019251518A1 (en) 2020-09-24
WO2019195897A1 (en) 2019-10-17
CN111971559A (zh) 2020-11-20

Similar Documents

Publication Publication Date Title
JP6430560B2 (ja) 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７
US11591599B2 (en) Method for the diagnosis, prognosis and treatment of cancer metastasis
US20170058360A1 (en) Methods for Prediction of Clinical Response to Radiation Therapy in Cancer Patients
JP7535270B2 (ja) 子宮内膜症の診断方法、病態モニタリング方法及びキット
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
TW201819639A (zh) 結腸直腸癌的糞便細菌標誌物
US9702879B2 (en) Methods and products for in vitro diagnosis, in vitro prognosis and the development of drugs against invasive carcinomas
WO2008128043A2 (en) Diagnostic and prognostic methods for renal cell carcinoma
JP2021534195A (ja) 標的ＴＧＦ−β阻害によるトリプルネガティブ乳がんの処置
JP2025509665A (ja) Ｐｒｍｔ５阻害剤を用いたがん診断および治療
KR20090053222A (ko) 체액 내 대장암 마커로서의 ｃｘｃｌ－１６유전자 및 이를이용한 대장암의 진단 및 치료에의 용도
JP2021521437A (ja) 処置に対する応答をモニターする方法
TWI762516B (zh) 針對ｆｚｄ１０之單株抗體及其用途
JP5885243B2 (ja) 胆管細胞癌の検出方法および予防・治療剤のスクリーニング方法
WO2008031165A1 (en) Methods and compositions for the diagnosis and treatment of tumours
JP2021522478A (ja) 選択された患者の心血管疾患を治療するための組成物および方法
WO2025044942A1 (en) Use of secreted cdcp1 for improved treatment of non-alcoholic steatohepatitis
JP7774310B2 (ja) 腎がん患者の抗がん剤抵抗性および予後予測方法、抗腎がん物質のスクリーニング方法、ならびに、腎がん治療用医薬組成物
KR20220141216A (ko) 유방암 진단을 위한 신규 바이오마커
WO2012164035A1 (en) Method for predicting the risk of developing a colonic neoplasia
Holleran The Role of Angiopoietins and Their Mediators in Symptomatic Small Bowel Angiodysplasia; Identifying Novel Diagnostic and Therapeutic Targets in Chronic Anaemia and Obscure Gastrointestinal Bleeding
WO2019056199A1 (zh) 卵巢癌生物标记及其应用
TWI702400B (zh) 偵側卵巢癌之方法、監控卵巢癌病患之卵巢癌發展之方法及可辨識切割型c3多胜肽之試劑的用途
WO2026044153A1 (en) Use of biomarkers in the diagnosis of pancreatic cancer
EP1526381A1 (en) Methods for in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230606

R150 Certificate of patent or registration of utility model

Ref document number: 7292306

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150